Received: 14 April 2022
Accepted: 1 September 2022
First Online: 29 September 2022
: Dr. Alessi-Severini received research grants from Pfizer and Merck for projects not involving SGLT-2 inhibitors or DPP-4 inhibitors. The remaining authors have no conflicts of interest to disclose.
: Research ethics board approvals were obtained at each participating institution (the Conjoint Health Research Ethics Board at the University of Calgary (AB); UBC Clinical Research Ethics Board (BC); The University of Manitoba Health Research Board (MB); the Health Sciences Research Ethics Board (NS); the University of Saskatchewan Biomedical Research Ethics Board (SK); and the Research Ethics Board of the CIUSSS West-Central Montreal Board (CPRD, QC)), except at ICES in Ontario, where research ethics board approval was not legally required. The informed consent was not required because this study used anonymized administrative data. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable